Teprotumumab BLA Submitted for Active Thyroid Eye Disease
Teprotumumab is an investigational fully human monoclonal antibody that works by inhibiting the insulin-like growth factor 1 receptor.
Graves’ Disease
Teprotumumab Effectively Reduces Proptosis in Active Thyroid Eye Disease
Teprotumumab effectively reduces proptosis in patients with active thyroid eye disease.
Early Treatment for Hyperthyroidism Reduces CV Morbidity, Mortality in Graves Disease
Early and intensive treatment for hyperthyroidism in Graves disease is associated with improvements in cardiovascular morbidity and all-cause mortality, regardless of treatment method used.
Case Study: Young Woman With Abnormal Thyroid Function Tests
A patient with no thyroid-related symptoms presents with an abnormal thyroid function test.
Maternal Thyroid Function in Pregnancy Linked to Childhood Risk for Disease
Maternal Graves disease and Hashimoto disease during pregnancy increases childhood risk for type 1 diabetes and schizophrenia, respectively.
Treatment With Alemtuzumab May Frequently Induce Thyroid Dysfunction
Investigators reviewed cases of patients with multiple sclerosis treated with alemtuzumab to determine the type and frequency of thyroid dysfunction.
Active Ophthalmopathy Benefits From Teprotumumab Treatment
Patients given teprotumumab were more likely to experience a response at 24 weeks vs placebo.
Rituximab Bests Methylprednisolone in Graves’ Orbitopathy
In a randomized, double-blind study, Rituximab was more effective in treating Graves’ orbitopathy than intravenous methylprednisolone.
Graves’ Ophthalmopathy Risk Decreased With Thyroidectomy, Statin Use
Statins and thyroidectomy may delay or prevent thyroid-associated ophthalmopathy in Graves’ disease.
Thyroid Antibody Levels Not Predictive of Clinical Manifestations of Graves’ Disease
Thyroid-specific autoantibody levels did not predict clinical features of Graves’ disease, including ophthalmopathy or goiter.
Next post in Thyroid
